Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(17)
•••
Comment by cpacon Feb 05, 2020 9:02am
193 Views
Post# 30645012

RE:would anyone think ticker BXRX is similar to ATE.. it looks

RE:would anyone think ticker BXRX is similar to ATE.. it looks I tried to dig into BXRX, but I couldn't entirely make sense of it... This is their third try getting approval... hopefully the third times the charm.  However, I couldn't get my mind around why they got rejected the first two times... this is an IV formulation of an existing drug... bulls said it was due to a 'labelling issue' ... if that was truly the case, that it was nothing to do with safety or efficacy and just how the product would be marketed/positioned, then I have to say management have to be pretty stupid to screw that up twice...  there were some other aspects of the story I just couldn't make sense of either... the stock was spun off from Recro, but the CEO and the CFO remain the same??
I have been wrong before and may well be wrong on BXRX, but it will be for the right reason... if you feel like you can't get comfortable with a biotech's story, avoid... there are plenty of other fish in the sea, lol.  In this case, I just added more to ATE instead.  A story that I think is more clear and obvious to me. :)  
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities